Sprycel® (dasatinib) Oral Tablets for Ph+ CML and ALL

What Sprycel® Is and How It Works

Sprycel® (dasatinib) is a tyrosine kinase inhibitor used to treat Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) and Ph+ acute lymphoblastic leukemia (Ph+ ALL). It targets BCR-ABL and SRC family kinases to slow leukemia cell growth. This Sprycel medication is taken as a tablet once daily. Strengths include 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg to match clinical needs.

Youdrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. We source from licensed, vetted international partner pharmacies to offer authentic brand medicines from a broad catalog at competitive Canadian pricing.

Common Sprycel uses include first-line therapy for chronic phase CML and for patients resistant or intolerant to prior therapy (such as imatinib). In advanced phases or in Ph+ ALL, it is used at higher doses. Many patients receive the Sprycel 100 mg tablet for chronic phase CML; Sprycel 70 mg and Sprycel 140 mg are used in other settings. You can read more science detail in Dasatinib 100 Mg Tablets How It Works In Cancer Therapy. The medicine is manufactured by Bristol Myers Squibb; some patients refer to it as BMS Sprycel or Sprycel Bristol Myers Squibb.

Dosage and Usage

• Adults with chronic phase CML: typically 100 mg once daily.
• Adults with accelerated phase, blast phase CML, or Ph+ ALL: commonly 140 mg once daily.
• Pediatrics: dosing is weight- or body-surface–based; use specialist guidance.
• Can be taken with or without food. Swallow tablets whole. Do not split, crush, or chew.
• Avoid grapefruit and grapefruit juice.
• Avoid proton pump inhibitors (PPIs) and H2 blockers. If an antacid is needed, administer at least 2 hours before or after dasatinib.
• Review interacting drugs. Strong CYP3A4 inhibitors/inducers may require avoidance or dose changes.
• Missed dose: skip and resume the next scheduled dose. Do not double dose.
• Monitoring includes blood counts, liver enzymes, and assessment for fluid retention or pleural effusion. ECG monitoring may be considered in patients at risk for QT prolongation.

• Store at 20–25 °C (68–77 °F); short excursions 15–30 °C (59–86 °F).
• Keep tablets in the original bottle with the desiccant. Protect from moisture.
• Keep out of reach of children and pets. Caregivers should avoid handling broken tablets.
• When you travel, carry Sprycel in your hand luggage with the labeled bottle.
• Bring extra days of supply and a copy of your prescription.
• Do not store in a bathroom or a hot car. Keep the bottle closed tightly.

Benefits and Savings

Sprycel treatment offers potent BCR-ABL inhibition with once-daily oral dosing. Many patients achieve rapid hematologic responses, and deeper molecular responses develop over time with continued therapy. Flexible strengths (including dasatinib 70 mg and dasatinib 140 mg) help clinicians individualize dosing for tolerability and goals of care.

Ordering from Canada can lower the Sprycel cost substantially. Typical savings are 60–80% versus common US retail pricing. The Sprycel price varies by strength and quantity; many people compare Sprycel 100 mg price with Sprycel 70 mg price depending on their prescribed dose. Multi-month supplies can reduce the Sprycel cost per month, and periodic bulk promotions may lower the per-month cost further. You can also set gentle reorder reminders so you do not run short.

For occasional promotions, see our sprycel coupon page for current offers.

Side Effects and Safety

• Low blood counts (thrombocytopenia, neutropenia, anemia)
• Headache, fatigue, dizziness
• Diarrhea, nausea, vomiting, abdominal pain
• Rash, pruritus
• Edema and fluid retention; pleural effusion may occur
• Muscle or joint pain
• Cough, dyspnea
• Fever or infection
• Elevated liver enzymes
• Bleeding events (nosebleeds, bruising)

Serious risks can include severe myelosuppression, clinically significant pleural effusion, pulmonary arterial hypertension, severe bleeding, QT prolongation, and rare liver injury. Embryo-fetal toxicity is a concern; effective contraception is advised during treatment and for a period after the last dose. Breastfeeding is not recommended while on dasatinib. Strong CYP3A4 inhibitors/inducers and acid-reducing agents can change exposure. Seek urgent care for signs of severe shortness of breath, chest pain, uncontrolled bleeding, or infection.

Onset Time

Hematologic improvements in Ph+ CML often appear within the first few weeks as counts stabilize. Many patients see complete hematologic response within 1–3 months. Cytogenetic and molecular responses typically deepen over 3–12 months. Symptom relief, such as reduced fatigue or splenic discomfort, may also improve over weeks. In Ph+ ALL, response often aligns with the chemotherapy cycle schedule when dasatinib is part of a protocol.

Compare With Alternatives

Imatinib is a first-generation TKI with extensive long-term data. Some patients switch to dasatinib for resistance or intolerance. Compared with imatinib, sprycel medicine can induce faster or deeper responses in select settings, but it carries distinct risks such as pleural effusion.

Nilotinib is another second-generation option. It is taken twice daily on an empty stomach and has specific cardiac and metabolic warnings. Dasatinib offers once-daily dosing with or without food, and monitoring focuses on counts and fluid retention. Choice often depends on mutation profile, comorbidities, and prior therapy.

Bosutinib is used after prior TKI therapy and is associated with more gastrointestinal effects. Ponatinib is reserved for cases with the T315I mutation or multi-TKI resistance because of vascular risks. Your oncology team weighs response goals, mutation status, and safety profiles when selecting a TKI. For broader context, see our Cancer condition hub.

Combination Therapy

• Ph+ ALL: often combined with multi-agent chemotherapy per protocol; dasatinib may continue as maintenance.
• CML: generally used as monotherapy; TKIs are not combined with each other.
• Central nervous system prophylaxis in Ph+ ALL may include intrathecal therapies.
• Manage reflux with antacids separated from dasatinib by at least 2 hours; avoid PPIs and H2 antagonists.
• Review concomitant medications for strong CYP3A4 interactions and adjust per specialist guidance.

Patient Suitability and Cost-Saving Tips

Sprycel medication is intended for patients with Ph+ CML (all phases) or Ph+ ALL as directed by an oncologist. It may not be appropriate in cases of uncontrolled cardiac disease, significant baseline QT prolongation, active bleeding, severe hepatic impairment, or a history of severe pleural effusion. Risk–benefit discussions are essential, especially in older adults or those with multiple comorbidities.

Pregnancy should be avoided during treatment. Discuss family planning, fertility considerations, and breastfeeding timing with the oncology team. Report new shortness of breath, chest discomfort, or rapid weight gain, which can indicate fluid retention.

To manage costs, compare strengths and pack sizes to see where the Sprycel price aligns with your prescription. Multi-month orders often lower the sprycel cost per month. Watch for a Sprycel discount during promotional periods. Reorder reminders help you avoid interruptions in therapy.

Authoritative Sources

Bristol Myers Squibb Sprycel patient and caregiver information

FDA application overview for dasatinib (Sprycel)

Health Canada Drug Product Database: search “dasatinib”

Order Sprycel® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This content is for educational purposes only and does not replace advice from your oncology team or other qualified healthcare professionals.